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Abstract 
Purpose: To develop transdermal patches of meloxicam (MLX) using chitosan and hydroxypropyl 
methylcellulose (HPMC) and polyvinyl alcohol (PVA) as hydrophilic polymers, polyamido amine 
(PAMAM) dendrimer as a permeation enhancer, and dibutyl pthalate as a plasticizer  
Methods: The patches were prepared by solvent casting evaporation technique using 3-factor, 3-level 
Box-Behnken design. The patches were evaluated for physical appearance, thickness, weight variation, 
folding endurance, drug content uniformity, tensile strength, moisture absorption and moisture loss, in 
vitro drug release, as well as by field-emission scanning electron microscopy (FESEM) and x-ray 
diffraction (XRD). A specially designed glass diffusion cell was used for the in vitro drug release study. 
The effect of concentrations of dependent variables (PAMAM G3, chitosan and dibutyl pthalate) on drug 
release was investigated. 
Results: The patches demonstrated satisfactory characteristics. PAMAM dendrimer significantly 
enhanced (p < 0.5) the permeation of MLX. A maximum of 85.7 % drug release was achieved in 24 h.  
Conclusion: Dendrimer increased the release of MLX by increasing its solubility and permeation 
through the membrane. Thus, dendrimer patches are a potentially suitable transdermal drug delivery 
system for the management of some diseased conditions. 
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Arthritis is an autoimmune disease and disorder 
of the joints characterized by inflammation of one 
or more joints of the body part [1,2]. The use of 
NSAID’s is ubiquitous in the management of 
arthritic condition due to their effectiveness as 
anti-inflammatory and analgesic activity [3]. 
Meloxicam (MLX) is a oxicam derivative, is a 
member of the enolic acid group of NSAID’s. 
MLX has been effectively used in symptomatic 
management of the rheumatoid arthritis and 
osteo arthritis. MLX have lower toxicity than the 
other NSAIDs with similar efficacy for reducing 
the pain and anti-inflammatory symptoms. 
NSAIDs including MLX is characterized by their 
gastrointestinal adverse effects which include 
ulceration, bleeding, inflammation and 
perforation of the stomach. So oral route is not 
obvious route for the administration of MLX. 
Considering all these issues it’s become 
mandatory to develop other drug delivery system 
Duan et al 
Trop J Pharm Res, April 2015; 14(4):   
 
584 
other than oral to overcome the problems 
associated with current delivery technology.  
Dendrimers are potential permeation enhancer 
as well as solubility enhancer [4,5].  
 
Dendrimers are monodisperse, hyper branched, 
three dimensional, tree-like macromolecules 
having host-guest entrapment properties.   Wang 
et al studied novel transdermal drug delivery 
system with polyhydroxyalkanoante (PHA) and 
starburst polyamidoamine dendrimers [6].  
Chauhan et al studied dendrimers mediated 
transdermal delivery to enhance bioavailability of 
indomethacin [7].  Vamsi et al investigated the 
effect of poly(amidoamine) (PAMAM) dendrimer 
on skin permeation of 5-fluorouracil [8]. 
  
Transdermal drug delivery system (TDDS) in the 
form of patch is an innovative technique for the 
application on skin to achieve systemic effects. 
The aim of this study was to develop an effective 
transdermal patch using dendrimer that would 






Meloxicam (MLX) was purchased from 
Shouguang Fukang Pharmacy Factory 
(Shandong, China), Polyamido amine dendrimer 
Generation 3 (PAMAM G3) was purchased from 
Sigma Aldrich, USA. Chitosan, hydroxypropyl 
methylcellulose (HPMC), polyvinyl alcohol (PVA), 
dibutyl pthalate, acetic acid and methanol were 
purchased from Shanghai Chemical C. 
(Shanghai, China). 
 
Preparation of transdermal patch 
 
Solvent casting evaporation was performed to 
prepare the patches on glass petri dish as 
described previously [9]. PVA (2 % dispersion) 
was prepared by dispersing the polymer in 
double-distilled water (20 ml) and heating to 40 
0C. The baking membrane was cast by pouring 
PVA dispersion (20 ml) on to the petri dish 
followed by drying in hot air oven at 55 oC for 8 h. 
The drug reservoir compartment was prepared 
by dissolving HPMC (1.5 %) in double distilled 
water (25 ml). To this solution, dibutyl Pthalate 
(10, 20 and 30 %) (plasticizer) and various 
concentrations of PAMAM dendrimer (0.3, 0.45 
and 0.6 %) was added. MLX (100 mg) dissolved 
in methanol (10 ml)was added drop by drop to 
the HPMC-plasticizer dispersion under slow 
stirring with magnetic stirrer. The whole 
dispersion containing the drug was cast on the 
PVA backing membrane and allowed to dry for 6 
h at 50 oC. The rate controlling membrane 
(consisting of chitosan) was prepared by 
dissolving the polymer in 2 % acetic acid, cast on 
the drug reservoir, followed by drying at 50 oC for 
4 h. The dry patch was removed from Petri dish 
and cut into small patches of 1 cm2 and kept in a 
desiccator containing silica as desiccant and 
used for further analysis. The composition of the 




Experiments were designed using Design Expert 
6.0.8 portable Stat-Ease, Inc. software. A 3-
factor, 3-level Box–Behnken design was used to 
derive a second order polynomial equation and 
construct contour plots to predict responses 
 
Evaluation of transdermal patches 
 
All patches were examined visually and 
inspected for smoothness, color and clarity. 
Thickness was measured at 5 different locations 
by using screw gauze and average thickness 
was determined. Individually, 10 patches from 
each batch were weighed and the mean weight 
was determined. Folding endurance test was 
performed to determine the strength of the patch 
and to check the efficiency of the plasticizer. It 
was determined by repeatedly folding the patch 
at the same place until it broke. The number of 
times the patch could be folded at the same 
place without breaking or cracking gave the 
value of folding endurance [10]. 
 
Drug content uniformity test was performed on 
three patches. Each patch was soaked and 
dissolved in 50 ml of methanol and resulting 
solution was filtered to remove undissolved 
residue. Aliquots were prepared and measured 
spectrophotometrically for drug content at 365 
nm. [9]. Mechanical properties and strength of 
the patches were determined by measuring their 
tensile strength. Tensile strength of the patch 
was determined with Universal strength testing 
apparatus (Hounsfield, Slinfold, Horsham, U.K.) 
[11].  
 
Moisture uptake was determined by first 
weighing each patch accurately and then placed 
in a desiccator containing silica as a desiccant. 
After 5 days, the patches were taken out and 
weighed individually. Percent moisture uptake 
was calculated as the difference between final 
and initial weight with respect to initial weight 
[12]. For moisture content determination, t, the 
patches were weighed accurately and kept in a 
desiccator containing anhydrous calcium 
chloride. After 5 days, the patches were taken 
out and weighed.  
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Table 1: Variable and three levels, and formulation design 
 
Independent variable Low level (-1) Medium level (0) High level (+1) 
A = PAMAM conc. (%) 0.3 0.45 0.6 
B = Chitosan conc. (%) 1 2 3 
C = DBP conc. (%) 10 20 30 
Dependent Variables    
Y1 = % DR (drug release)    
Composition of and Diagnostic Statistics  for Y1 
Batch Factor Actual DR Predicted DR Residual 
 A B C Y1   
F1 -1 0 +1 33.25 34.79 -1.54 
F2 0 0 0 52.57 56.21  -3.64 
F3 0 0 0 50.24 56.21 -5.97 
F4 0 -1 -1 55.78 60.68 -4.90 
F5 +1 0 +1 69.9 73.67 -3.77 
F6 -1 +1 0 30.4 34.28 -3.88 
F7 0 2 0 51.78 56.21 -4.43 
F8 +1 +1 0 72.65 73.16 -0.51 
F9 0 -1 +1 59.67 56.72 2.95 
F10 0 +1 -1 62.86 55.70 7.16 
F11 -1 0 -1 42.23 38.75 3.48 
F12 0 +1 +1 60.45 51.74 8.71 
F13 0 0 0 52.38 56.21 -3.83 
F14 +1 0 -1 78.24 77.63 0.61 
F15 +1 1 0 85.71 78.14 7.57 
F16 0 0 0 52.35 56.21 -3.86 
F17 -1 -1 0 45.1 39.26 5.84 
 
Percent moisture loss (which is a measure of 
moisture content) is generally used to determine 
whether a patch has sufficient. Patches with very 
less moisture content tend to become brittle in 
nature was calculated as the difference between 
final and initial weight with respect to initial 
weight [12]. 
 
Specially designed glass diffusion cell was used 
to carry out in vitro release study. Cellophane 
dialysis membrane was soaked previously for 24 
h in pH 7.5 phosphate buffer [13]. This 
membrane was stretched around one end of the 
diffusion cell. The working surface area of the 
membrane was 2.5 cm2. The tube (donor 
compartment) was immersed in a glass beaker 
containing pH 7.5 phosphate buffer (receptor 
compartment) in such a way that the membrane 
just touched the receptor medium. A weighed 
transdermal patch (1 cm2) was placed on the 
cellophane dialysis membrane. The receptor 
medium was maintained at 37 ± 0.5 °C and 
stirred at 50 rpm by keeping it on hot plate 
magnetic stirrer. Aliquots (5 ml) of samples were 
withdrawn from the receptor medium at 
predetermined time intervals and replaced with 
equal volume of fresh buffer to maintain sink 
conditions. Samples were analysed with 
spectrophotometrically at 365 nm and drug 
release was computed. 
 
Surface morphology of the drug- loaded patches 
were studied using scanning electron microscopy 
(FESEM-S 4800, Hitachi, Japan). 
 
The crystalline and amorphous nature of MLX, 
chitosan, HPMC and drug-loaded patch were 




Physical characteristics of patches 
 
F2, F4, F5, F9 were smooth on their surface 
while F10, F3, F6, F8, F12, F14, F16 were rough. 
All data is shown in Table 2. Some of the 
batches were found to be transparent in nature. 
The thickness of the patches was found to be in 
the range of 0.02 ± 0.15 to 0.04 ± 0.28 mm. The 
tensile strength of the patches was found in the 
range of 0.30 ± 0.0040 to 0.62 ± 0.38 kg/cm2. 
The weight of patches was found to be in the 
range of 0.13 ± 0.25 gm to 0.16 ± 0.30 gm. Also 
the uniformity of drug content of drug among all 
the batches patches were observed and ranged 
from 95.36  ±  1.15 to 98.47 ± 0.91 % shown in. 
Folding endurance of the hydrophilic 
chitosan/HPMC based patches ranged from 
132.24 ± 3.21 to 189.14 ± 3.24. Moisture 
absorption was in the range of 1.23 ± 0.25 to 
3.72 ± 0.28 %. 
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Table 2: Physical characteristics of patches 
 








F1 T 138.20 ± 2.25 0.30 ± 0.01 1.70 ± 0.22 1.20 ± 0.25 
F2 S 150.21 ± 3.20 0.31 ± 0.38 1.69 ± 0.20 2.30 ± 0.27 
F3 R 165.25 ± 3.26 0.39 ± 0.37 2.56 ± 0.21 1.24 ± 0.30 
F4 S 145.20 ± 4.30 0.40 ± 0.30 2.55 ± 0.25 1.32± 0.35 
F5 S 178.23 ± 3.15 0.60 ± 0.42 1.70 ± 0.27 1.28 ± 0.32 
F6 R 168.43 ± 3.25 0.62 ± 0.38 3.69 ± 0.12 3.23 ± 0.42 
F7 T 152.54 ± 3.28 0.56 ± 0.20 2.45± 0.15 3.31 ± 0.57 
F8 R 189.14 ± 3.24 0.58 ± 0.54 3.50 ± 0.22 3.50 ± 0.45 
F9 S 165.25 ± 3.23 0.55 ± 0.89 2.56 ± 0.23 2.21± 0.29 
F10 S 139.25 ± 3.37 0.35 ± 0.40 3.22 ± 0.22 2.20± 0.15 
F11 T 125.33 ± 3.51 0.36 ± 0.45 3.70 ± 0.26 3.24 ± 0.25 
F12 R 132.24 ± 3.21 0.38 ± 0.59 1.56 ± 0.11 1.19 ± 0.53 
F13 T 148.20 ± 3.27 0.59 ± 0.23 2.40 ± 0.27 1.20± 0.55 
F14 R 175.23 ± 3.32 0.40 ± 0.25 3.72 ± 0.28 1.28 ± 0.51 
F15 T 169.35 ± 3.39 0.34 ± 0.24 1.23 ± 0.25 4.12 ± 0.24 
F16 R 170.36 ± 3.24 0.33 ± 0.28 1.72 ± 0.30 2.50 ± 0.21 
F17 T 185.30 ± 3.26 0.45 ± 0.45 1.65 ± 0.28 2.70 ± 0.25 
Note:  T = transparent, S = smooth, R = rough 
 
Optimized in vitro drug release  
 
In vitro drug release was performed in pH 7.4 
phosphate buffer using a modified diffusion cell. 
Drug release in 24 h was in the range of 33.25 
(F1) to 85.71 % (F15). The polynomial equation 
obtained for DR (Y1) is given by Eq 1. 
 
Y1 = + 56.21 + 19.44A - 2.49B - 1.98C ……. (1) 
 
A positive value in Eq 1 equation represents the 
synergistic effect of the independent variable. + 
19.44A represents the positive or synergistic 
effect of independent factor A (dendrimer 
concentration) on in vitro drug release. A 
negative value represents the inverse 
relationship (antagonistic effect). The value, - 
2.49B, represents the antagonistic effect of 
independent factor B (chitosan concentration) on 
in vitro drug release. The suggested model for 
the Y1 was linear as shown in Table 3. The value 
of correlation coefficient (R2) for the response Y1 
was 0.8874 which indicates the good fit for the 
linear model. The p-value for the Y1 model was 
found to be < 0.0001 which clearly indicates the 
model is statistically significant. Also among the 
three independent variables selected only factor 
A (Dendrimer Conc.) was found to be statistically 
significant (p <  0.0001) while the effect of factor 
B (p = 0.2234) and C (p = 0.3274) was not 
statistically significant (Table 3). Diagnostics 
case statistics for various response variables are 
shown in Table 3.  The drug release pattern 
shown by the patches had wide variation from 
33.25 % (F1) to 85.71 % (F15). A comparative in 
vitro drug release is shown in Figure 1. 
 
 
Table 3: Regression analysis for response Y1 and ANOVA of models 
 
Models R2 Adjusted  R2 Predicted R2 Std. Dev Press Remarks 
Response Y1       
Linear 0.8874 0.8615 0.7914 5.50 729.59 Suggested 
     2FI 0.8905 0.8248 0.5498 6.19 1574.77 …….. 
Quadratic 0.9373 0.8566 0.0113 5.60 3458.22 …….. 
Cubic 0.9990 0.9958  0.95 + Aliased 
Regression equations of the fitted model: Y1 = +56.21 + 19.44A - 2.49B - 1.98C 
ANNOVA for response Y1 
Source DF Sum of squares Mean square F value P-value 
Model for Y1 3 3104.17 1034.72 34.17 < 0.0001 
A 1 3023.31 3023.31 99.83 < 0.0001 
B 1 49.50 49.50 1.63 0.2234 
C 1 31.36 31.36 1.04 0.3274 
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                                Figure 1: In vitro drug release profile of MLX transdermal patches 
 
The counter plots were constructed to elucidate 
the effect of dependent variables on the 
independent variable. The effect of A and B on 
drug release at DBT concentration of 20 is 
showed in Figure 2. 
 
 
Figure 2: Effect of PAMAM and chitosan on drug 
release of MLX from patches 
 
As can be seen from counter plots, the drug 
release was increased as the concentration of 
PAMAM dendrimer in patches increases. When 
concentration of PAMAM was maintained at -1 
level the drug release was increased from 30.4 
% (F6) to 45.1 % (F17). At 0 level the further 
increase in drug release was found, in this case 
the drug release was increased from 50 % (F9) 
to 62 % (F10). 69 % (F5) to 85 % (F15) drug 
release was increased in case of + 1 level. From 
the counter plot Figure 3, the effect of chitosan 




Figure 3: Effect of PAMAM and dibutyl pthalate on 
drug release of MLX from patches 
 
When the concentrtion of chitosan was 
maintained at -1 level the drug release was found 
to be in the range of 45 (F17) to 85 % (F15). At 0 
level the decrease in drug release was observed 
and it was found to be the 33 (F1) to 78 % (F14). 
Further decrease in drug release was observed 
when the chitosan concentration was maintain at 
+ 1 level and this case the drug release was 30.4 
(F6) to 72 % (F8). From Figure 3 it was clear that 
when concentration of DBT was maintained at - 1 
level the drug release was found to be 42.23 
(F11) to 78.24 % (F14) but when it was 
maintained at 0 level the drug release was 30.4 
Duan et al 
Trop J Pharm Res, April 2015; 14(4):   
 
588 
% (F6) to 85.71 % (F15). At + 1 level the drug 
release was 33.25 % (F1) to 69.9 % (F5).  
 
Surface morphology and crystallinity 
 
FE-SEM photographs of the patches are shown 
in Figure 4A and B, and they display smooth and 
rough surface of the patches. 
 
XRD study was performed to determine the 
crystalline and amorphous nature of the drug and 
polymer. It is clear from the Figure 5 that the 
crystalline peaks of the pure MLX have been 
disappeared in MLX loaded transdermal patches. 
Pure MLX was 78.30 % crystalline and 21.7 % 
amorphous in nature. But when MLX was 
entrapped in patch system along with dendrimer, 
chitosan and HPMC polymer the crystallinity of 
MLX was decreased to 42.54 %. Therefore, in 
the final formulation, the MLX was 57.46 % 




The smoothness of the patches was attributed to 
the content of plasticizer in patches. The 
concentration of DBT imparted the smoothness 
and roughness to the patches. Some of the 
batches were found to be rough in nature but still 
the patches were pharmaceutically acceptable. 
The increase in thickness in patches was due to 
presence of backing layer and rate controlling 
membrane. The drug reservoir compartment in 
all batches was sandwiched between these two 
 
 
                 Figure 4: SEM of patches.  




                         Figure 5: X-ray diffractograms showing various peaks of MLX, HPMC, chitosan and patch 
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layers that lead to increase in thickness of the 
patches. Due to presence of hydrophilic HPMC 
polymer there were no any signs of crack on the 
patches. Also the presence of plasticizer DBT 
played imp role for the minimization of cracking 
of the patches. There was no any wide variation 
in weights of patches found. Nearly all patches 
were of the same weight. The possible reason for 
the good content uniformity in drug was may be 
due to minimum weight variation among the 
patches that lead to give uniformity in the drug 
content. These results obvious indicated that the 
solvent casting-evaporation technique employed 
to formulate was capable for producing patches 
with minimum weight variability with uniform drug 
content. The folding endurance test was 
performed to determine the ability of the patch to 
evaluate the flexibility and to endure rupture. This 
test indicates that the formulated patches would 
maintain integrity and would not break after 
application on the skin. The results showed 
higher folding endurance capacity with increasing 
concentration of the hydrophilic polymer blend 
system. It is clear that all the patches had low 
moisture content, which helped the formulations 
to remain stable and reduce cracking, wrinkling 
and brittleness during long term storage. 
Actually, a small amount of moisture content is 
always desirable to maintain the stability of the 
patches and protection of patches from the 
microbial contamination. From this study it was 
concluded that the increase in the concentration 
of hydrophilic chitosan/HPMC polymer was 
directly proportional to the increase in moisture 
uptake of the patches. 
  
As the concentration of dendrimer increased the 
drug release from the patches also increased 
linearly. PAMAM dendrimers possesses empty 
internal cavities as well as amine functional 
groups on the outer shell. Empty internal cavities 
are able to encapsulate hydrophobic guest 
molecules in the macromolecule interior [14]. 
MLX could have been encapsulated by the 
empty internal cavities of PAMAM dendrimer. 
With amine terminated dendrimers, the proposed 
mechanism for solubility enhancement of MLX 
was electrostatic interactions between the 
terminal amine groups of dendrimers and –OH 
group of MLX and molecular encapsulation. So it 
is now clear that the linear increase in drug 
release was due to solubility enhancement effect 
of dendrimer on MLX. Extremely low water 
solubility of MLX could have been significantly 
improved by the PAMAM dendrimer that 
facilitated the drug release from the drug 
reservoir compartment of hydrophilic HPMC 
polymer. Though the effect of chitosan on drug 
release was not statistically significant, still we 
could predict that as the concentration of 
chitosan increased from the -1 level to + 1 level, 
decrease in drug release was observed. 
Chitosan is hydrophillic polymer it forms gel 
when comes in contact with the water. Due to the 
gelling property of the chitosan in presence of 
aqueous medium, it forms the rate controlling 
layer for the patch system. So gelling of chitosan 
has retarded the release of MLX from the patch 
system. Also chitosan is pseudo plastic material 
which is excellent viscosity enhancing agent and 
viscosity increases with increase in chitosan 
concentration.  
 
The combined effect of gelling property and 
viscosity enhancing effect of chitosan has 
controlled the release of MLX from the patch 
system. In case of plasticizer DBT there was no 
any linear relationship between concentration of 
DBT and drug release from the patches. The 
effect of DBT on drug release was statistically 
insignificant (p = 0.3274). It is clear from the 
SEM images that the prepered patches were 
having smooth surface as well as rough surface. 
In figure the wrinkles were observed on rough 
surface patches this may be due to the 
overdrying of the patches that laid to formation of 
rough appearance on the patches. The patches 
didn’t show any sign of cracks or pores on the 
surface which reveals the cohesive structure of 
the polymer matrix. XRD results indicate that 





Dendrimers were found to be potential tool for 
the enhancement of the drug release from the 
patches. Dendrimer increased drug release of 
MLX by increasing the solubility and permeation 
through the membrane. Thus, dendrimer patches 
are a potential drug delivery system for the 
transdermal management of rheumatoid arthritis 
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